公开(公告)号：US20200277378A1

公开(公告)日：2020-09-03

申请号：US16764102

申请日：2018-11-16

Applicant: Novartis AG

Inventor： Catherine Anne Sabatos-Peyton ,  Jennifer Marie Mataraza ,  Kenzie MacIsaac ,  Eunice Kwak ,  Jason Faris ,  Glenn Dranoff ,  Marion Wiesmann ,  Fiona Sharp ,  Adam Crystal ,  John Scott Cameron ,  Robert Martin Strieter ,  Lilli Petruzzelli ,  Shamsah Kazani ,  David Andrew Sandham ,  Neil John Press ,  Keith Hoffmaster

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.

公开(公告)号：US20240252668A1

公开(公告)日：2024-08-01

申请号：US18286664

申请日：2022-04-15

Applicant: Anne-Sophie BLUEMMEL ,  Kathrin BUNTIN ,  Joseph Anthony D'ALESSIO ,  Liqiong FAN ,  Boris FESSLER ,  Doris GABRIEL ,  Dominik HAINZL ,  Keith HOFFMASTER ,  Shwetha IYER ,  Eshita KHERA ,  Eusebio Manchado ROBLES ,  Pierre MAUDENS ,  Dominik PISTORIUS ,  Roee RAMOT ,  Vincent ROMANET ,  Kuno WUERSCH ,  Padmaja YERRAMILLI-RAO ,  Novartis AG

Inventor： Liqiong Fan ,  Dominik Hainzl ,  Roee Ramot ,  Shwetha Iyer ,  Joseph Anthony D'Alessio ,  Kuno Wuersch ,  Dominik Pistorius ,  Eusebio Manchado Robles ,  Kathrin Buntin ,  Doris Gabriel ,  Boris Fessler ,  Pierre Maudens ,  Vincent Romanet ,  Anne-Sophie Bluemmel ,  Keith Hoffmaster ,  Eshita Khera ,  Padmaja Yerramilli-Rao

IPC: A61K47/68 ,  A61P35/00 ,  C07K11/02 ,  C07K14/47 ,  C07K16/28 ,  C12N9/00 ,  C12N9/02 ,  C12N9/04 ,  C12N9/18 ,  C12N15/52 ,  C12P21/02 ,  C12R1/01 ,  G01N33/574

CPC classification number: A61K47/6849 ,  A61K47/6811 ,  A61K47/6865 ,  A61P35/00 ,  C07K11/02 ,  C07K14/4722 ,  C07K16/28 ,  C12N9/0006 ,  C12N9/0073 ,  C12N9/18 ,  C12N9/93 ,  C12N15/52 ,  C12P21/02 ,  C12Y301/01001 ,  G01N33/57492 ,  C12R2001/01

Abstract: This application discloses microorganisms and methods of producing GNAQ/GNA11 inhibitors and methods of making antibody drug conjugates of anti-PMEL17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The disclosure also relates to formulations comprising antibody drug conjugates of anti-PMEL 17 antibodies or antigen binding fragments conjugated to a GNAQ/GNA1 inhibitor and methods of treating or preventing cancer using the formulations.